

Patient				
Patient name:				
Date of birth:	<input type="checkbox"/> Male <input type="checkbox"/> Female	Height:	Weight:	lb kg
Address:		City:	State:	ZIP:
Home number:	Work number:	Cell number:	Best time to call: <input type="checkbox"/> a.m. <input type="checkbox"/> p.m.	
Last 4 of Social Security:		Ethnicity:		
Primary language:		Allergies:	<input type="checkbox"/> No known drug allergies	

Provider				
Physician name:		Practice name:		
National Provider Identifier (NPI) number:		State license number:		
Address:		City:	State:	ZIP:
Drug Enforcement Administration (DEA) number:		Phone:	Fax:	
Key office contact:		Phone:		

Insurance
 *Please provide a copy of the insurance card (front and back).

Clinical information				
Diagnosis: <input type="checkbox"/> G35 (Multiple Sclerosis) <input type="checkbox"/> Other ICD:		Diagnosis Date:		
Type: <input type="checkbox"/> Relapsing-remitting <input type="checkbox"/> Secondary-progressive <input type="checkbox"/> Primary-progressive <input type="checkbox"/> Progressive-relapsing <input type="checkbox"/> Clinically isolated syndrome				
Previously treated: <input type="checkbox"/> Avonex <input type="checkbox"/> Betaseron <input type="checkbox"/> Copaxone <input type="checkbox"/> Gilenya <input type="checkbox"/> Plegridy <input type="checkbox"/> Rebif <input type="checkbox"/> Other: _____				Dates:

Please attach copies of pertinent labs and clinicals in order to assist us in obtaining prior authorization approval.

Prescription information				
Medication	Dose/Strength	SIG	Quantity	Refills
<input type="checkbox"/> Aubagio®	<input type="checkbox"/> 7 mg Tab <input type="checkbox"/> 14mg Tab	<input type="checkbox"/> Take one tablet by mouth once daily.	1 month supply	
<input type="checkbox"/> Avonex®	30 mcg <input type="checkbox"/> Pen <input type="checkbox"/> PFS <input type="checkbox"/> Vial	<input type="checkbox"/> Dose Titration: (PFS Only) • Week 1: Inject 7.5mcg IM once weekly Week 2: Inject 15mcg IM once weekly • Week 3: Inject 22.5mcg IM once weekly • Week 4+: Inject 30mcg IM once weekly thereafter. <input type="checkbox"/> Maintenance Dose: Inject 30mcg IM once weekly	1 month supply	
<input type="checkbox"/> Dalfampridine	<input type="checkbox"/> 10 mg tablets	<input type="checkbox"/> Take one tablet by mouth once daily.	1 month supply	
<input type="checkbox"/> Betaseron® <input type="checkbox"/> Extavia®	<input type="checkbox"/> 0.3 mg vial	<input type="checkbox"/> Dose Titration: • Weeks 1 – 2: Inject 0.0625mg/0.25mL SubQ every other day • Weeks 3 – 4: Inject 0.125mg/0.50mL SubQ every other day • Weeks 5 – 6: Inject 0.1875mg/0.75mL SubQ every other day • Weeks 7+: Inject 0.25mg/1mL SubQ every other day <input type="checkbox"/> Maintenance dose: Inject 0.25mg SubQ every other day	1 month supply	
<input type="checkbox"/> Copaxone® <input type="checkbox"/> Glatramer <input type="checkbox"/> Glatopa	<input type="checkbox"/> 20 mg PFS <input type="checkbox"/> 40 mg PFS	<input type="checkbox"/> Inject 20mg SubQ once daily <input type="checkbox"/> Inject 40mg SubQ three times a week, at least 48 hours apart on the same three days each week	1 month supply	
<input type="checkbox"/> Gilenya®	<input type="checkbox"/> 0.5 mg capsule	<input type="checkbox"/> Take one capsule by mouth daily with or without food	1 month supply	
<input type="checkbox"/> Ocrevus™	<input type="checkbox"/> 300 mg/10ml vial	<input type="checkbox"/> Infuse 300 mg IV on day 1, followed by 300 mg IV infusion 2 weeks later <input type="checkbox"/> Infuse 600 mg IV administered once every 6 months (beginning 6 months after the first 300 mg dose).	<input type="checkbox"/> 1 vial <input type="checkbox"/> 2 vials	
<input type="checkbox"/> Plegridy®	<input type="checkbox"/> 63mcg/94mcg Starter Pak <input type="checkbox"/> 125mcg <input type="checkbox"/> Pen <input type="checkbox"/> PFS	<input type="checkbox"/> Initial dose: Inject 63mcg SubQ day 1, then 94mcg SubQ day 15 <input type="checkbox"/> Maintenance dose: Inject 125mg SubQ on day 29 and then every two weeks thereafter	1 month supply <input type="checkbox"/> Starter Kit	
<input type="checkbox"/> Rebif®	<input type="checkbox"/> PFS Starter <input type="checkbox"/> Pen Starter <input type="checkbox"/> 22mcg PFS <input type="checkbox"/> 22mcg Pen <input type="checkbox"/> 44mcg PFS <input type="checkbox"/> 22mg Pen	<input type="checkbox"/> Titration Pack 22mcg Weeks 1-2: Inject 4.4mcg SubQ three times weekly. Weeks 3-4: Inject 11mcg SubQ three times weekly. <input type="checkbox"/> Titration Pack 44mcg Weeks 1-2: Inject 8.8mcg SubQ three times weekly. Weeks 3-4: Inject 22mcg SubQ three times weekly <input type="checkbox"/> Maintenance Dose: <input type="checkbox"/> 22mcg <input type="checkbox"/> 44mcg SubQ three times weekly	1 month <input type="checkbox"/> Starter kit	
<input type="checkbox"/> Tecfidera™	<input type="checkbox"/> Titration Pack <input type="checkbox"/> 120mg Cap <input type="checkbox"/> 240mg Cap	<input type="checkbox"/> Titration Pack -Take 120 mg capsule by mouth twice a day for 7 days followed by 240 mg capsule by mouth twice a day <input type="checkbox"/> Maintenance Dose: Take 240mg capsule by mouth twice daily	1 month <input type="checkbox"/> Starter Kit	
<input type="checkbox"/> Mayzent	<input type="checkbox"/> 0.25mg Tab <input type="checkbox"/> 2mg Tab	<input type="checkbox"/> Take 2 mg once daily, beginning on Day 6. <input type="checkbox"/> Take 1 mg once daily, beginning on Day 5	1 month	
<input type="checkbox"/> Other				

PRESCRIBER SIGNATURE: PRESCRIBER SIGNATURE IS REQUIRED TO VALIDATE PRESCRIPTIONS. (STAMPS NOT ACCEPTED)

Prescriber signature:	Prescriber signature:
<input type="checkbox"/> Dispense as written/Do not substitute	Date:
<input type="checkbox"/> Substitution permitted/Branded exchange permitted	Date:

For states requiring handwritten expressions of product selection, use this area (e.g. medically necessary, may not substitute, dispense as written, etc.).

Confidentiality Notice: This fax transmission, and any documents attached to it, may contain confidential and/or protected health information. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this document is prohibited. If you have received this transmission in error, please immediately notify us by telephone at 855-287-7888 and destroy the original transmission and its attachments without reviewing, printing, copying, or otherwise saving them. © PerformSpecialty, LLC. | PerformSpecialty® is a registered trademark of PerformRx, LLC.